Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function
| Autor: | Keiyu Matsumoto, Shusuke Akamatsu, Yoshiyuki Matsui, Takeshi Sano, Osamu Ogawa, Takashi Kobayashi, Akihiro Hamada, Toru Sakatani, Kenji Nakamura, Atsuro Sawada |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Urology Renal function Kidney General Biochemistry Genetics and Molecular Biology Carboplatin chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Humans Medicine In patient Platinum Retrospective Studies Urothelial carcinoma Pharmacology Cisplatin Carcinoma Transitional Cell Chemotherapy business.industry Systemic chemotherapy Gemcitabine Treatment Outcome Urinary Bladder Neoplasms chemistry business Research Article medicine.drug |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background/aim Standard chemotherapy for advanced urothelial carcinoma (UC) patients with moderate renal dysfunction has not yet been established. Patients and methods We retrospectively assessed outcomes of patients with advanced UC who underwent first-line chemotherapy with full-/reduced-dose gemcitabine plus cisplatin (GC-f/GC-r) or full-/reduced-dose gemcitabine plus carboplatin (G-Car-f/G-Car-r) according to renal function. Results Seventy-eight patients were included in this study. The objective response rate was 42%, 30%, 42%, and 27% for the GC-f, GC-r, G-Car-f, and G-Car-r groups, respectively. For the GC-r and G-Car-f groups, the median progression-free survival and the median overall survival was 4.5 vs. 7.0 months (p=0.07) and 7.5 months vs. 12.0 months (p=0.124), respectively. Grade 3/4 thrombocytopenia occurred more frequently in the GC-r group than the G-Car-f group (80% vs. 38%, p=0.021). Conclusion G-Car-f could be more beneficial than GC-r for patients with advanced UC who have moderate renal dysfunction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|